Literature DB >> 20172145

Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis.

Marc Riquet1, Karima Achour, Christophe Foucault, Françoise Le Pimpec Barthes, Antoine Dujon, Aurélie Cazes.   

Abstract

BACKGROUND: Many studies focus on bronchial microscopic residual disease (R1) after resection for lung cancer, although R1 also concerns vascular and soft tissues. Our purpose was to study the R1 prognosis at different resection margins and to compare it with the prognosis for those having complete resection (R0).
METHODS: We reviewed the clinical records of 4,026 patients from two centers who underwent surgery in view of cure. Despite perioperative frozen section, 216 patients (5.4%) proved R1 and were classified into seven types according to R1 anatomic site: bronchus, peribronchus, great vessels and atrium, mediastinum and pericardium, chest wall, lung tissue, and lymph nodes. Patients who were classified as R0 and R1 were compared, and R1 patients were further studied according to R1 margins.
RESULTS: Frequency of R1 increased with the T and N values and type of resection (lobectomies, 3.3% [70 of 2,041 patients]; pneumonectomies, 8.8% [126 of 1,308 patients]; p < 10(-6)). Five-year survival rates for R1 patients were lower than those for R0 patients (20% versus 46%; p < 10(-6)), and were not modified by the degree of T and N involvement or adjuvant therapy, but were better in bronchial and peribronchial (48.4% of R1 patients) than in extrabronchial R1 (26.3% versus 15.6%; p = 0.023). Multivariate analysis confirmed R1 to be an independent factor of poor prognosis (p = 0.0008), after N, T, and age.
CONCLUSIONS: Long-term survival is possible in case of an R1 margin, but 5-year survival rates are jeopardized. Poor efficacy of adjuvant therapy and global outcome indicate advanced disease or reflect tumor cell aggressiveness, rather than surgical insufficiency, when prevention of R1 margins is guided by frozen-section examination and scrupulously respected. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20172145     DOI: 10.1016/j.athoracsur.2009.11.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  23 in total

1.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Unexpected extensions of non-small-cell lung cancer diagnosed during surgery: revisiting exploratory thoracotomies and incomplete resections.

Authors:  Christophe Foucault; Pierre Mordant; Bertrand Grand; Karima Achour; Alex Arame; Antoine Dujon; Françoise Le Pimpec Barthes; Marc Riquet
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-23

Review 3.  Intraoperative molecular imaging to identify lung adenocarcinomas.

Authors:  Andrew D Newton; Gregory T Kennedy; Jarrod D Predina; Philip S Low; Sunil Singhal
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 4.  Oncologic Quality Indicators in Thoracic Surgery.

Authors:  Jessica Hudson; Tara Semenkovich; Varun Puri
Journal:  Thorac Surg Clin       Date:  2017-08       Impact factor: 1.750

5.  Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.

Authors:  Qingyun Liu; Chaoren Zhao; Penghui Jiang; Dawei Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

6.  [Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Authors:  K Junker; R Büttner; T Langer; D Ukena
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

7.  [Application and interpretation of the R classification for lung cancer : Results of a survey of certified lung cancer centers].

Authors:  H Hoffmann; K Junker; C Kugler; P A Schnabel; A Warth
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

Review 8.  Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions.

Authors:  Gal Shafirstein; Athar Battoo; Kassem Harris; Heinz Baumann; Sandra O Gollnick; Joerg Lindenmann; Chukwumere E Nwogu
Journal:  Ann Am Thorac Soc       Date:  2016-02

9.  Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.

Authors:  Raymond U Osarogiagbon; Chun Chieh Lin; Matthew P Smeltzer; Ahmedin Jemal
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

10.  Differential outcomes of residual disease in surgically-resected non-small cell lung cancer and the importance of guideline-concordant adjuvant therapy.

Authors:  Dustin K Lieu; Li Ding; Elizabeth A David; Sean C Wightman; Scott M Atay; P Michael McFadden; Anthony W Kim
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.